<DOC>
	<DOCNO>NCT01684150</DOCNO>
	<brief_summary>The purpose study determine safe dose EPZ-5676 , evaluate safety EPZ-5676 patient advance hematologic malignancy , conduct preliminary assessment anti-leukemia activity EPZ-5676 patient acute leukemias bearing rearrangement MLL gene . Currently study MLL-r restricted/expansion phase enrol patient rearrangement involve MLL gene , include 11q23 partial tandem duplication ( PTD ) .</brief_summary>
	<brief_title>A Phase 1 , Open-Label , Dose-Escalation &amp; Expanded Cohort , Continuous IV Infusion , Multi-center Study Safety , Tolerability , PK &amp; PD EPZ-5676 Treatment Relapsed/Refractory Patients With Leukemias Involving</brief_title>
	<detailed_description>A subset patient acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) harbor rearrangement MLL gene , detect either cytogenetic fluorescent situ hybridization evaluation time diagnosis . A protein call DOT1L play important role malignant process leukemia . EPZ-5676 molecule block activity DOT1L , therefore evaluate treatment patient MLL-rearranged leukemia . The dose escalation portion complete . Currently study expansion phase patient MLL-r MLL-PTD receive EPZ-5676 28-day continuous intravenous infusion ( CIV ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>1 . Male female patient age ≥ 18 year . 2 . Patients relapse /refractory AML , ALL , MLL rearrangement MLL gene , include 11q23 PTD , eligible expand cohort : At least one prior therapy ; Refractory disease recent therapy , disease recurrence follow remission recent therapy ; Received fail know effective therapy disease ; Not candidate allogeneic stem cell transplantation &gt; 10 % blast biopsydocumented leukemia cutis myeloid sarcoma . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 4 . Patients must follow clinical laboratory value : Serum creatinine ≤2 mg/dL creatinine clearance &gt; 60 mL/minute ; Total bilirubin ≤2.0 time ULN institution , unless consider due Gilbert 's syndrome ; ALT AST ≤ twice upper limit normal ( ULN ) , unless consider due organ leukemic involvement ; Absolute neutrophil count ≥1,000/µL ( unless due document leukemic involvement bone marrow time study entry ) Platelets ≥100,000/µL ( unless due document leukemic involvement bone marrow time study entry ) . PT aPTT &lt; 1.5 time ULN 5 . Able willing give write informed consent . 6 . Life expectancy least 3 month 1 . Uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement . 2 . Active heart disease 3 . Receiving standard treatment hematologic malignancy . 4 . Receiving strong CYP3A4 inhibitors/ inducer . 5 . Known history cerebrovascular accident past 6 month . 6 . Known bleeding diathesis . 7 . Known , active ( symptomatic ) involvement central nervous system leukemia . 8 . On immunosuppressive therapy . 9 . Known active infection . 10 . Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Advanced hematologic malignancy</keyword>
	<keyword>Epizyme</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Mixed Lineage Leukemia ( MLL )</keyword>
</DOC>